57135-877, Euromieh IR of IRAN
Phone: 98 +21 66960206
In The Name of God,
-Investment to produce vaccine against asthma allergy and cancers Ø§ÛŒÙ…ÙˆÙ†ÙˆØªØ±Ø§Ù¾ÛŒ Ø³Ø±Ø·Ø§Ù†ØŒ Ø§ÛŒÙ…ÙˆÙ†ÙˆØªØ±Ø§Ù¾ÛŒ Ø¢Ø³Ù… Ùˆ Ø¢Ù„Ø±Ú˜ÛŒ Ùˆ …Ø³Ø±Ù…Ø§ÛŒÙ‡ Ú¯Ø°Ø§Ø±ÛŒ Ø¨Ø±Ø§ÛŒ ØªÙˆÙ„ÛŒØ¯ÙˆØ§Ú©Ø³Ù† Ø¢Ø³Ù… Ø¢Ù„Ø±Ú˜ÛŒ Ùˆ Ø³Ø±Ø·Ø§Ù†
Biotherapy , Immunotherapy , Cancer , Asthma , HIV+ & AIDS , Adjuvants , Anti-Cancer Vaccines , Auto-Antigens , Specific Antigens, Th-1 Cells activators (CD4+ T cells) , Specific Immunotherapy , Allergic Disorders , Allergy , Cytolytic T Lymphocytes , Breast Cancer , Acute Lymphoblastic Leukemia (ALL) , Glioblastoma , Hepatoma , astrocytoma , Ferittin , rgp63 , BALB/c Mice , Haz-1 Breast Cancer , blastogenesis index (Stimulation Index S.I.) . Skin- Test (PPD Skin Test)/ g-IFN (gamma IFN) , Cell Mediated Immunity (CMI), Investment
(This is a new hope for all Cancers, HIV+ Allergic, Asthmatic patients)
I would like to inform some of my activities on preparing of Th-1 cells activators and Auto-specific Antigens. The story when started that I have seeking for treating cancers with non-specific adjuvants. I could prepare two kinds of them. I have done Phase I and II clinical trails. These adjuvants could heal up to 30% of breast cancer and increase up to 300% of survival lives in mice. They are safe in human cancer patients. I distribute these adjuvants to other Doctors. One of them mentioned that, when he used these vaccines in cancerous patients who had also asthma, their asthma healed and disappeared. So, I have used these vaccine with in three moderate asthmatic patients who have asthma between 2 to 8 years. After four months injection of vaccine with a 5-7 days per/w, their asthma were cured. So, when I was seeking for the real action of these adjuvants effects, I found that activities of Th-2 cells make incensement of asthma because of IL-5 function. IL-5 increase the number of Eos. cells in the blood. And there is correlation between of number of Eos. and asthma. On the other hand, when the activities of Th-1 cells increase they produce gamma-IFN. This cytokine could have negative feedback for Th-2 cells activity. As a results, it seems that these adjuvants could help asthma. These vaccines could heal more than 90% of Children asthma. Also they could help to heal of allergies, viral infections, HIV+, MDR-TB, All kinds of Cancers. They could control cancers. This Adjuvant + Specific Auto-Antigen Immunotherapy Method is ready to give service to the all patients in the would free of charges. Just send me a letter with your medical report, I will guide you how to obtain vacciens.
Finally, we invite you to have investment in this important of Technology.
With best regards,
Dr. Saleh Mohaghegh Hazrati, Ph.D.
E mail ; firstname.lastname@example.org
Mohaghegh Hazrati S, et. al. G2, PC, G2F in allergic asthma. Iranian J of Pediatrics 2004;13 (2)supl. :30-31.
Mohaghegh Hazrati S, et. al. Effect of Auto-antigens and Th-1 activator adjuvants on pituitary adenoma of prolactinoma. 6th International congress of endocrine disorders. Oct 5-9, 2001, Iranian J. of Endocrine and Metabolism, O-28, pp 22.
Mohaghegh Hazrati S, et al. Review of Immunotherapy with Th-1 activator and Auto-vaccines against cancers. Seminar on Diagnostic and new methods of Cancer treatment. June 6-8 2001, Babol University of Medical Sciences, IR of Iran.
Mohaghegh Hazrati S, et al. Immunotherapy of brain tumors and other cancers with immunopotent adjuvants and auto-antigens (case report). 23 April 2001, 11th International congress of Immunology, Sweden.
Mohaghegh Hazrati S & Mohtarami F. Why Th-1 activator vaccines could effective for Immunotherapy of chemical gas injured patients. The Role of Basic Sciences on defense against new wars. 12-13 March 2001 Tehran, University of Imam Hossein (A), IR of Iran.
Mohaghegh Hazrati S, et al. The Role of GW-1, GM-1, PPD-A, PPD-B as immunopotent Adjuvants in cell Mediated Immune response against recombinant gp63 in BALB/c Mice. April 10-13, 2000, 9th International Congress on Infectious Diseases Buenos Aires, Argentina.
Mohaghegh Hazrati S, et al. Immunotherapy of pituitary Adenoma of Prolactinoma with Adjuvants (Cases Report). 17-19 May 2000, 5th Iranian congress of Immunology and Allergy, Tehran IR of Iran.
Mohaghegh Hazrati S, et al. A novel an invasive and metastatic adenocarcinoma of breast cancer (HAZ-1) in small white laboratory mice. (Complementary Report). Sept. 6-9, 1999, The Fifth Biochemistry Congress of Uromia, IR of Iran.
Mohaghegh Hazrati S., et al. Biotherapy in Cancers, Asthma and Infectious and other diseases. Nov 1999, First Azarbidjanian Congress on Biotechnology Uromia, IR of Iran.